| Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract (NCT04069299) | H. Lee Moffitt Cancer Center and Research Institute | 2019-09-25 |
| Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery (NCT04091165) | H. Lee Moffitt Cancer Center and Research Institute | 2019-09-23 |
| Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion (NCT03722407) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-28 |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma (NCT03381183) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-21 |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma (NCT03921073) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-20 |
| Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas (NCT04055688) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-15 |
| Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance (NCT04101526) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-15 |
| Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma (NCT03927274) | H. Lee Moffitt Cancer Center and Research Institute | 2019-06-20 |
| Avelumab With Radiotherapy in Patients With Leptomeningeal Disease (NCT03719768) | H. Lee Moffitt Cancer Center and Research Institute | 2019-06-10 |
| Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer (NCT03923270) | H. Lee Moffitt Cancer Center and Research Institute | 2019-06-06 |
| Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (NCT03598309) | H. Lee Moffitt Cancer Center and Research Institute | 2019-06-05 |
| Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia (NCT03514017) | H. Lee Moffitt Cancer Center and Research Institute | 2019-05-31 |
| Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma (NCT03834623) | H. Lee Moffitt Cancer Center and Research Institute | 2019-05-14 |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (NCT03874325) | H. Lee Moffitt Cancer Center and Research Institute | 2019-04-26 |
| Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia (NCT03760523) | H. Lee Moffitt Cancer Center and Research Institute | 2019-04-18 |
| Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia (NCT03904199) | H. Lee Moffitt Cancer Center and Research Institute | 2019-04-04 |
| Florida Pancreas Collaborative Next Generation Biobank (NCT03851133) | H. Lee Moffitt Cancer Center and Research Institute | 2019-03-04 |
| CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (NCT03605927) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-15 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (NCT03611738) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-01 |
| Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases (NCT03807765) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-30 |
| Emotional Support Messages Following a Cancer Diagnosis (NCT03840109) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-30 |
| SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer (NCT03614949) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-29 |
| Development of a Mindfulness-Based Treatment for the Reduction of Alcohol Use and Smoking Cessation (NCT03734666) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-14 |
| Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 (NCT03630809) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-10 |
| TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT03686488) | H. Lee Moffitt Cancer Center and Research Institute | 2018-12-20 |
| Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) (NCT03663166) | H. Lee Moffitt Cancer Center and Research Institute | 2018-11-20 |
| Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer (NCT03748719) | H. Lee Moffitt Cancer Center and Research Institute | 2018-11-19 |
| Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (NCT03712943) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-23 |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia (NCT03575325) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-11 |
| Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide (NCT03411031) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-04 |
| Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy (NCT03543189) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-03 |
| Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers (NCT03656133) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-26 |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (NCT03511196) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-17 |
| Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients (NCT03674138) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-12 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (NCT03630120) | H. Lee Moffitt Cancer Center and Research Institute | 2018-08-06 |
| Applying mHealth to Tobacco-related Health Disparities (NCT03404596) | H. Lee Moffitt Cancer Center and Research Institute | 2018-07-16 |
| Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung (NCT02466568) | H. Lee Moffitt Cancer Center and Research Institute | 2018-07-01 |
| Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (NCT03501368) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-27 |
| Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (NCT03543969) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-14 |
| HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (NCT03387553) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-06 |
| Improving Sleep in BMT Survivors (NCT03537963) | H. Lee Moffitt Cancer Center and Research Institute | 2018-05-15 |
| Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) (NCT03906110) | H. Lee Moffitt Cancer Center and Research Institute | 2018-04-03 |
| Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma (NCT03426891) | H. Lee Moffitt Cancer Center and Research Institute | 2018-03-16 |
| Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (NCT03406715) | H. Lee Moffitt Cancer Center and Research Institute | 2018-03-15 |
| Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (NCT03384914) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-19 |
| Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (NCT03377023) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-02 |
| Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers (NCT03332498) | H. Lee Moffitt Cancer Center and Research Institute | 2018-01-24 |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (NCT03370276) | H. Lee Moffitt Cancer Center and Research Institute | 2017-12-20 |
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (NCT03290079) | H. Lee Moffitt Cancer Center and Research Institute | 2017-12-15 |
| Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer (NCT03137693) | H. Lee Moffitt Cancer Center and Research Institute | 2017-11-29 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer (NCT03215810) | H. Lee Moffitt Cancer Center and Research Institute | 2017-10-11 |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (NCT03177291) | H. Lee Moffitt Cancer Center and Research Institute | 2017-09-26 |
| Facilitating Smoking Cessation With Reduced Nicotine Cigarettes (NCT02796391) | H. Lee Moffitt Cancer Center and Research Institute | 2017-09-07 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (NCT02780609) | H. Lee Moffitt Cancer Center and Research Institute | 2017-07-20 |
| Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (NCT03112590) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-23 |
| Patient Navigation in the Adolescent and Young Adult (AYA) Cancer Population (NCT03176576) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-13 |
| A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-08 |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat (NCT02802163) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-01 |
| Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms (NCT03072043) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-18 |
| Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative (NCT05064410) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-11 |
| Refining and Testing the Electronic Social Network Assessment Program (eSNAP) (NCT03026699) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-05 |
| Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (NCT02779855) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-02 |
| Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (NCT02964078) | H. Lee Moffitt Cancer Center and Research Institute | 2017-04-25 |
| Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma (NCT02989870) | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-27 |
| Biobank for African American Prostate Cancer Research in Florida (NCT03232411) | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-22 |
| Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma (NCT03071406) | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-14 |
| Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder (NCT02901548) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-16 |
| Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study (NCT02803333) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-16 |
| Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (NCT03043599) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-13 |
| FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas (NCT03042780) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-01 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors (NCT02948946) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-09 |
| Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (NCT02945800) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-25 |
| Spanish-Language Smoking Cessation Trial (NCT02945787) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-24 |
| Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer (NCT02973750) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-20 |
| Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (NCT02935309) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-14 |
| Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers (NCT02829918) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-05 |
| Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) (NCT02851056) | H. Lee Moffitt Cancer Center and Research Institute | 2016-09-27 |
| XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (NCT02721459) | H. Lee Moffitt Cancer Center and Research Institute | 2016-09-07 |
| Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas (NCT02829931) | H. Lee Moffitt Cancer Center and Research Institute | 2016-08-22 |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma (NCT02631590) | H. Lee Moffitt Cancer Center and Research Institute | 2016-07-05 |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) (NCT02722941) | H. Lee Moffitt Cancer Center and Research Institute | 2016-06-10 |
| A Combined Cell Therapy Approach to the Treatment of Neuroblastoma (NCT02745756) | H. Lee Moffitt Cancer Center and Research Institute | 2016-04-14 |
| Validation Study on the Impact of Decipher® Testing - VANDAAM Study (NCT02723734) | H. Lee Moffitt Cancer Center and Research Institute | 2016-04-13 |
| Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) (NCT02638090) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-22 |
| Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma (NCT02652455) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-08 |
| Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma (NCT02611037) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-04 |
| Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention (NCT02588339) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-04 |
| Fermented Wheat Germ Extract in Women With Ovarian Cancer (NCT02411565) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-01 |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer (NCT02586675) | H. Lee Moffitt Cancer Center and Research Institute | 2016-02-23 |
| Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (NCT02502864) | H. Lee Moffitt Cancer Center and Research Institute | 2016-02-09 |
| Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer (NCT02572284) | H. Lee Moffitt Cancer Center and Research Institute | 2016-01-27 |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer (NCT02440425) | H. Lee Moffitt Cancer Center and Research Institute | 2015-10-20 |
| Smoking-cessation: A Spanish-Language Clinical Trial (NCT02611076) | H. Lee Moffitt Cancer Center and Research Institute | 2015-10-15 |
| AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer (NCT02513563) | H. Lee Moffitt Cancer Center and Research Institute | 2015-10-13 |
| Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (NCT02575300) | H. Lee Moffitt Cancer Center and Research Institute | 2015-10-09 |
| Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention (NCT02592447) | H. Lee Moffitt Cancer Center and Research Institute | 2015-09-29 |
| Using MC1R Genotype to Impact Melanoma Risk Behavior (NCT03509467) | H. Lee Moffitt Cancer Center and Research Institute | 2015-08-03 |
| Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas (NCT02313272) | H. Lee Moffitt Cancer Center and Research Institute | 2015-07-28 |